Regional · European Union

EU-wide position versus national implementation

Regional › European Union EMA personal import cost per milligram formulary

Solved Under review

Solved by a.finnegan_rd in post #8

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

Jump to the accepted answer →

Under review. A claim in this topic has been challenged and a moderator has asked for a source. The status is a label, not a judgement, and it is removed when the source arrives or the claim is withdrawn.

b.brandtTL2 Moderator17 Apr 2025#1

EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did.

Documenting an access outcome, dated, because everything in this category expires.

As of May 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

36 likes 15mo

coldchain_liuTL3Regular27 Apr 2025#2

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

8 likes 15mo

s.girardTL2 Moderator4 May 2025#3

Coming back to the opening post, because the follow-up matters more than the original answer.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

0 likes 15mo

logbook_erinTL3Regular10 May 2025#4

s.girard, post #3: Coming back to the opening post, because the follow-up matters more than the original answer. Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available. Go to post

Picking up post #3: that is the part I would want checked first.

Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.

0 likes in reply to #3 15mo

v.kirchnerTL2 Moderator16 May 2025#5

coldchain_liu, post #2: Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation. Go to post

Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.

26 likes in reply to #2 14mo

v.szaboTL3Analytical chemist22 May 2025#6

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

13 likes 14mo

m.nascimentoTL2 Moderator27 May 2025#7

I read post #5 twice before replying, because I had assumed the opposite.

Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.

2 likes 14mo

a.finnegan_rdTL2Dietitian Solution1 Jun 2025 · edited#8

France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.

7 likes 14mo

v.bergstromTL2 Moderator6 Jun 2025#9

logbook_erin, post #4: Picking up post #3: that is the part I would want checked first. Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents. Go to post

On post #5 — agreed on the reasoning, with one qualification.

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

9 likes in reply to #4 14mo

VPoulsenTL3Regular11 Jun 2025#10

post #9 answers the question as asked. The question underneath it is different.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

2 likes in reply to #2 14mo

isotonic_sheetTL3Regular15 Jun 2025 · edited#11

Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.

13 likes in reply to #3 13mo

ni.kravchenkoTL2 Moderator20 Jun 2025#12

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

27 likes 13mo

r.jhannsdttirTL3Regular24 Jun 2025#13

This follows post #10 rather than contradicting it.

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

0 likes 13mo

r.sobczakTL2 Moderator29 Jun 2025#14

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

4 likes 13mo

maintenance_modeTL3Regular3 Jul 2025#15

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

19 likes in reply to #3 13mo

k.pereiraTL2 Moderator7 Jul 2025#16

Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.

0 likes 13mo

r.venkatesanTL3Wiki editor12 Jul 2025#17

Picking up post #14: that is the part I would want checked first.

2 likes 13mo

p.krastevTL2 Moderator16 Jul 2025#18

Coming back to post #16, because the follow-up matters more than the original answer.

8 likes 12mo

coldchain_liuTL3Regular20 Jul 2025#19

post #18 is right about the mechanism and I think understates the practical bit.

26 likes 12mo

a.ilungaTL2 Moderator24 Jul 2025#20

r.sobczak, post #14: Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available. Go to post

Worth separating two things that post #16 runs together.

0 likes in reply to #14 12mo

an.zamoraTL228 Jul 2025#21

Collapsed as off-topic by two members at trust level 3 or above

EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.

RodriguesTL3Regular1 Aug 2025#22

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

0 likes 12mo

n.ramosTL2 Moderator5 Aug 2025#23

Coming back to post #21, because the follow-up matters more than the original answer.

Italy: AIFA controls reimbursement through a note system. Weight-management indications have not attracted public reimbursement. Regional health authorities add further variation.

0 likes 12mo

SHermansenTL2Member9 Aug 2025#24

Picking up post #21: that is the part I would want checked first.

Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.

19 likes 12mo

h.brandtTL2 Moderator12 Aug 2025#25

v.kirchner, post #5: Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules. Go to post

8 likes in reply to #5 11mo

r.venkatesanTL3Wiki editor16 Aug 2025#26

SHermansen, post #24: Picking up post #21: that is the part I would want checked first. Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation. Go to post

post #25 is right about the mechanism and I think understates the practical bit.

2 likes in reply to #24 11mo

p.trevinoTL2 Moderator20 Aug 2025#27

I read post #25 twice before replying, because I had assumed the opposite.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

0 likes 11mo

isotonic_sheetTL3Regular24 Aug 2025#28

26 likes 11mo

ai.wikstromTL2 Moderator27 Aug 2025#29

On post #25 — agreed on the reasoning, with one qualification.

Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.

0 likes in reply to #24 11mo

crossover_entryTL3Regular31 Aug 2025#30

coldchain_liu, post #19: post #18 is right about the mechanism and I think understates the practical bit. Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents. Go to post

post #29 answers the question as asked. The question underneath it is different.

0 likes in reply to #19 11mo

This topic was referenced in

EMA product information as a primary sourceRegional › European Union · 74 replies
[2026 update] EU-wide position versus national implementationRegional › European Union · 2 replies
EMA product information as a primary source — does this still hold?Regional › European Union · 150 replies

Promoted into the documentation commons. The content of this topic is maintained at Access notes: Spain, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Topic	Participants	Replies	Views	Activity
About the European Union category Regional › European Union EMA personal import cost per milligram Pinned Wiki Closed EMA positions, national differences within the EU, and cross-border purchase rules. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…	+1	5	18k	10mo
[2026 update] EU-wide position versus national implementation Regional › European Union personal import cost per milligram formulary EMA Solved On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of…		2	54k	19mo
Coming back to: Cross-border purchase rules within the EU Regional › European Union EMA cost per milligram personal import Cross-border purchase rules within the EU Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…	+12	16	2.8k	11mo
EMA product information as a primary source Regional › European Union personal import formulary EMA Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…	+70	74	7k	8mo
Reimbursement variation across member states Regional › European Union EMA personal import cost per milligram Reimbursement variation across member states Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…	+7	11	39k	3mo

Topic	Participants	Replies	Views	Activity
Revisiting: List price versus negotiated price versus what you pay Access › Pricing cost per milligram compounding data table formulary Revisiting: List price versus negotiated price versus what you pay — setting out what I have, and where I think it stops being reliable. A coverage question with the paperwork detail included, since that is…	+24	28	50k	12mo
Second pass at: Manufacturer assistance programmes and their eligibility rules Access › Pricing cost per milligram data table compounding formulary Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in…	+13	17	1.8k	16mo
Irish differences from the UK position — what changed since Regional › UK & Ireland personal import cost per milligram NHS Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this category…	+8	12	782	1d
External review after an internal denial Access › Insurance & coverage appeals prior authorisation insurance formulary Solved External review after an internal denial Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…		2	18k	1mo
Cross-border purchase within the EU: the actual rules Access › International MHRA EMA telehealth NHS Solved Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is…	+6	10	41k	11mo

EU-wide position versus national implementation

This topic was referenced in

Suggested topics

Related topics — sharing the tags EMA, personal import, cost per milligram